Infant Bacterial Therapeutics Past Earnings Performance
Past criteria checks 0/6
Infant Bacterial Therapeutics's earnings have been declining at an average annual rate of -17.9%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 98.4% per year.
Key information
-17.9%
Earnings growth rate
-16.6%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 98.4% |
Return on equity | -40.3% |
Net Margin | -159,828.6% |
Next Earnings Update | 07 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Infant Bacterial Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -123 | 15 | 120 |
30 Sep 23 | 0 | -122 | 7 | 122 |
30 Jun 23 | 0 | -99 | 5 | 99 |
31 Mar 23 | 0 | -69 | 4 | 67 |
31 Dec 22 | 0 | -65 | 1 | 65 |
30 Sep 22 | 0 | -42 | 1 | 40 |
30 Jun 22 | 0 | -34 | 1 | 32 |
31 Mar 22 | 0 | -65 | 1 | 63 |
31 Dec 21 | 0 | -45 | 1 | 44 |
30 Sep 21 | 0 | -55 | 1 | 54 |
30 Jun 21 | 0 | -74 | 1 | 73 |
31 Mar 21 | 0 | -73 | 1 | 72 |
31 Dec 20 | 0 | -72 | 1 | 71 |
30 Sep 20 | 0 | -73 | 1 | 72 |
30 Jun 20 | 0 | -65 | 1 | 64 |
31 Mar 20 | 0 | -44 | 1 | 44 |
31 Dec 19 | 0 | -46 | 1 | 46 |
30 Sep 19 | 0 | -43 | 1 | 43 |
30 Jun 19 | 0 | -40 | 1 | 39 |
31 Mar 19 | 0 | -32 | 1 | 30 |
31 Dec 18 | 0 | -41 | 1 | 38 |
30 Sep 18 | 0 | -26 | 1 | 24 |
30 Jun 18 | 0 | -22 | 1 | 21 |
31 Mar 18 | 0 | -37 | 1 | 36 |
31 Dec 17 | 0 | -36 | 1 | 35 |
30 Sep 17 | 0 | -41 | 1 | 41 |
30 Jun 17 | 0 | -44 | -2 | 47 |
31 Mar 17 | 0 | -42 | -2 | 44 |
31 Dec 16 | 0 | -38 | -2 | 40 |
30 Sep 16 | 0 | -19 | -1 | 30 |
30 Jun 16 | 0 | -7 | 3 | 24 |
31 Mar 16 | 0 | 0 | 3 | 18 |
31 Dec 15 | 0 | 0 | 3 | 17 |
31 Dec 14 | 0 | 0 | 0 | 7 |
Quality Earnings: 9IB is currently unprofitable.
Growing Profit Margin: 9IB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 9IB is unprofitable, and losses have increased over the past 5 years at a rate of 17.9% per year.
Accelerating Growth: Unable to compare 9IB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9IB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: 9IB has a negative Return on Equity (-40.33%), as it is currently unprofitable.